ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Taisho Pharmaceutical Holdings Co., Ltd.

  • 11,390.00 JPY
  • +100.00
  • +0.89%
  • Japan
    Jan 23, 2019
  • Ticker
    TKS(4581)
  • Prev. close
    11,290
  • Market cap (JPY)
    1,017.67B
  • Market cap (USD)
    9,278.17M
  • Shares
    90.13M

Business Summary

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management and administration of its group companies that manufactures and sells over-the-counter (OTC) drugs, foods, and other goods, etc. It operates through the following segments: Self-Medication and Prescription Pharmaceutical. The Self-Medication segment conducts research and development (R&D), manufacturing and sale of over-the-counter drugs, quasi-drugs, food, and general medical and hygiene supplies. The Prescription Pharmaceutical segment handles R&D, manufacturing, and sale of ethical drugs. It also provides the manufacture and sale of prescription pharmaceuticals; and businesses incidental or related thereto. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue280,138M2,527.58M
Gross Profit182,984M1,650.99M
Operating income36,977M333.62M
Income before tax48,070M433.71M
Net income31,679M285.82M
EBITDA48,357M436.30M
Diluted EPS396.203.57
Dividends Per Share1100.99
Total Assets800,157M7,523.80M
Total liabilities108,838M1,023.39M
Total equity675,231M6,349.13M
Operating cash flow39,852M359.56M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 295,969M 290,489M 289,956M 279,750M 280,138M
Gross Profit 184,694M 178,249M 176,813M 178,225M 182,984M
Operating income 41,683M 31,974M 28,878M 31,965M 36,977M
Income before tax 51,316M 40,162M 35,809M 41,956M 48,070M
Net income 32,692M 24,528M 22,473M 28,781M 31,679M
EBITDA 54,072M 44,914M 41,351M 43,635M 48,357M
Diluted EPS 403.06 302.41 277.60 359.93 396.20
Dividends Per Share 110 110 100 110 110
Total Assets 728,442M 768,092M 759,049M 771,222M 800,157M
Total liabilities 116,509M 114,850M 115,922M 106,132M 108,838M
Total equity 600,263M 640,056M 629,249M 649,938M 675,231M
Operating cash flow 60,233M 33,714M 43,058M 40,066M 39,852M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 2,954.62M 2,644.25M 2,414.60M 2,583.40M 2,527.58M
Gross Profit 1,843.77M 1,622.56M 1,472.40M 1,645.85M 1,650.99M
Operating income 416.11M 291.05M 240.48M 295.18M 333.62M
Income before tax 512.28M 365.58M 298.19M 387.45M 433.71M
Net income 326.36M 223.27M 187.14M 265.78M 285.82M
EBITDA 539.79M 408.84M 344.34M 402.95M 436.30M
Diluted EPS 4.02 2.75 2.31 3.32 3.57
Dividends Per Share 1.09 1.00 0.83 1.01 0.99
Total Assets 7,073.28M 6,404.76M 6,753.40M 6,921.13M 7,523.80M
Total liabilities 1,131.32M 957.68M 1,031.38M 952.45M 1,023.39M
Total equity 5,828.64M 5,337.13M 5,598.54M 5,832.70M 6,349.13M
Operating cash flow 601.29M 306.89M 358.56M 369.99M 359.56M

Valuation Measures

Mar 2018
PER26.37
ROA4.03%
ROE4.78%
Operating margin13.19%
Profit margin11.30%

Key executives

  • President & Representative Director: Akira Uehara
  • Director, Head-Audit, Finance & Legal Affairs: Ken Uehara
  • Head-Information Technology Planning: Osamu Kitatani
  • Director & Executive Vice President: Shigeru Uehara
  • Director, Head-Personnel & General Affairs: Tetsu Watanabe

Shareholders

  • The Uehara Memorial Foundation (16.6%)
  • Taisho Pharmaceutical Holdings Co., Ltd. (11.3%)
  • UEHARA SHOJI (8.7%)
  • Sumitomo Mitsui Financial Group, Inc. (5.1%)
  • Uehara Museum Foundation (4.3%)
  • Mitsubishi UFJ Financial Group, Inc. (4.0%)
  • UEHARA AKIRA (2.3%)
  • Kajima Corp. (1.8%)
  • Sumitomo Chemical Pension Fund (1.6%)
  • Sumitomo Chemical Co., Ltd. (1.5%)

Contact Details

Related Companies

  • Kosei SA de CV
  • Biofermin Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.

Competitors

  • Monster Beverage Corporation
  • LT Group, Inc.
  • Infraestructura Energetica Nova SAB de CV
Last Updated on 23 Jan, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media